Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
15.35
+0.08 (0.52%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Contineum Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $22.86. The average 1-year stock price forecast is 48.93% higher than the current stock price, while the lowest is $16 (+4.23%) and the highest is $28 (+82.41%).
Price Target: $22.86 (+48.93%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Buy Reiterates $26 | Buy | Reiterates | $26 | +69.38% | Jul 31, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $22 → $23 | Buy | Reiterates | $22 → $23 | +49.84% | Jul 31, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 31, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $24 | Buy | Maintains | $24 | +56.35% | Jul 30, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | +4.23% | May 14, 2026 |
Financial Forecast
Revenue This Year
6.88M
Revenue Next Year
1.83M
from 6.88M
Decreased by -73.37%
EPS This Year
-1.56
from -2.17
EPS Next Year
-1.82
from -1.56
EPS and Forward PE are based on non-GAAP adjusted numbers.